Epidemiology Database

AI-Driven Epidemiology Intelligence
Patient Burden Forecast

Access validated, expert-curated epidemiology enhanced by AI to understand disease burden, patient segmentation, and long-term trends across indications and geographies. Transform complex epidemiological data into dynamic, decision-ready insights built for forecasting, portfolio planning, and commercial strategy to take your business planning to the next level.

● Multi-indication, multi-geography coverage

● AI-powered synthesis across epidemiology models and reports

● Transparent, analyst-grade intelligence you can trust

DelveEpiAI - DelveInsight

What is the burden of IPF-associated cough across the seven major markets?

A: In 2026, diagnosed prevalent IPF cough cases are highest in the US (82,110), followed by Japan (17,457) and the UK (13,521), with meaningful patient populations across France, Italy, Spain, and Germany underscoring a sizable unmet clinical need across the 7MM. Below is the table summarizing the patient burden across the study period for the 7MM countries:

500+ Reports in library

Pharma markets...

📊

500+

Reports in library

TRUSTED BY

A Data-Driven

Disease Epidemiology Database

Driven by advanced analytics and AI-powered modeling, our epidemiology database delivers precise patient population insights. It offers deep sub-segmentation across indications for different leading geographies like the US, EU4, and Japan, enabling users to explore disease patterns, trends, patient journeys, and growth opportunities across leading markets with exceptional granularity.

Powered by a global network of KOLs, our epidemiology intelligence platform strengthens predictive modeling with insights from frontline researchers and practitioners. Whether you’re assessing disease burden, prevalence, incidence, diagnosed populations, defining patient populations, identifying unmet needs, or evaluating market potential, our ecosystem unites epidemiology trends analysis and advanced forecasting tools to support confident, data-driven strategic planning.

Forecast upto 2034
Country Specific Analysis
Patient Pool Assessment
In-depth Disease Segmentation
Treatable Patient Population with Highest Unmet Need

Patient Population Segmentation

Precision Insights for Smarter Decision-Making

An epidemiology dashboard for understanding disease burden across geographies, leveraging patient population segmentation and delivering precision insights for smarter decision-making.

🌍

Country-Specific Patient Journeys

Our AI-driven platform delivers detailed historical and forecast epidemiological data through 2034 with country-level granularity across leading markets, viz. 7MM, offering insights into diagnosis patterns, treatment pathways, and disease progression.

📊

Data-Driven Disease Estimation

The healthcare epidemiology analytics platform provides the total prevalence or incidence of diseases within multiple therapy areas, tailored to each specific indication that helps in identifying affecting changes in diagnosis trends.

🔬

Drug-Treated & Treatable Forecasts

Assess the total market potential and addressable segments by tracking changes in patient populations over time through our interactive epidemiology dashboard. Project both drug-treated and drug-treatable populations upto 2034 forecasts.

💊

Patient Population Growth Analysis

Make informed decisions on a potential asset’s market potential by analyzing patient population growth across leading markets and understanding disease segmentation based on diagnosis status, treatment patterns, disease stage, and severity.

AI-Powered Epidemiology Intelligence

💬

Expert-Driven Insights, Accelerated by AI

Leverage expert-curated epidemiology enhanced by AI to answer critical questions across diseases, geographies, and patient segments. Move faster from data to decision with multi-indication insights that transform complex epidemiological data into clear, actionable intelligence.

📑

Cross-Report Intelligence at Scale

Seamlessly synthesize insights across multiple epidemiology models, organized by therapeutic area, geography, and patient segment. Identify emerging trends, correlations, and strategic signals without manual model review. Explore disease burden and patient segmentation through an AI-powered intelligence layer that accelerates strategic decision-making.

How does the US metastatic CRC patient pool break down by mutation over time?

● DelveEpiAI

KRAS-mutant mCRC remains the largest and fastest-growing segment, driven primarily by KRAS G12D. BRAF V600E and dMMR/MSI-H subpopulations also expand steadily, reinforcing the importance of biomarker-driven strategies in mCRC.

Unique Selling Propositions

Why Teams Choose DelveInsight?

We harness data-driven Insights through advanced, customizable epidemiology analytics platform, enabling healthcare providers to make informed decisions that enhance patient outcomes.

🏭

Comprehensive Expert Insights

Leverage insights from leading KOLs and disease experts to deliver comprehensive, indication-specific epidemiology analyses across multiple therapeutic areas.

📊

In-Depth Incidence & Prevalence Insights

Gain a complete understanding of disease burden and patterns over the year. Analyze over 500 diseases and procedures for actionable market intelligence.

🌐

Major Markets Reach

Gain detailed, disease-specific historical and forecasted patient pool analysis and patient population trends upto 2034 forecasts across the major leading markets.

⚙️

Customized Solutions

Customized reports and research solutions designed around your specific indication, geography, and business objectives, delivered in flexible formats to meet your needs.

Patient Burden

Analysis and Forecasting

Advanced data insights and analytics to drive informed decision-making and strategic planning

Vast KOL Network

Unparalleled insights from various KOLs across different therapeutic areas

In-house Database

Reliable resources for insightful and data-driven solutions

Epidemiology Forecasting

Patient population forecasting upto 10 years, inclusive of patient trends.

Vast Geography Coverage

In-depth country-wise insights spanning across 7+ geographies.

Rare Disease Analysis

Track down the patient trends of ultra-rare disease with a vast network of KOLs.

100% Post Sale Support

1 analyst/account for real-time support to provide assistance to our clients.

Request A Call Back

Case Studies

Real Outcomes for Real Teams

PATIENT JOURNEY

Enhancing the Hypertension Patient Journey

Explore how a leading pharmaceutical company sought to deepen its understanding of the hypertension patient journey across multiple markets: the US, UK, Japan, Switzerland, Italy, and France.

Epidemiology